18 May 2007
Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: Safety and symptom control
Zbigniew Serafin, Maciej Karolkiewicz, Piotr Strześniewski, Władysław Lasek, Michał Bryczkowski, Zbigniew WolskiMed Sci Monit 2007; 13(1): 98-104 :: ID: 482390
Abstract
Background: Primarily palliative renal embolization is a relatively rare procedure which is indicated in patients with unresectable kidney malignancies and in patients in poor general condition. The aim of this paper was to evaluate the role of primarily palliative transarterial renal embolization for the treatment of inoperable patients with renal cell carcinoma, assessing the indications, safety, and efficacy of this procedure.Material and Methods: Seventy-three patients scheduled for palliative embolization between 1998 and 2005 were retrospectively analyzed regarding their medical history, the procedure report, and data from the early postoperative period. Results: Sixty-six of the 73 patients presented with renal cell carcinoma stage IV. The most common indication for embolization was hematuria (34%), followed by flank pain (32%), prophylaxis in stage IV (25%), lack of consent for surgery (7%), and poor general condition (3%). Embolizations were performed under local anesthesia with a mixture of enbucrilate and iodinated oil, with the use of additional embolizing materials in two cases. The procedure eliminated hematuria in 100% of cases and removed the loin pain completely in 72%. Migration of the embolizing material was observed in 10% of cases, and in 4% it resulted in symptomatic occlusion of the lower extremity distal arteries. Postembolic syndrome was noted in 92% of the patients. Conclusions: Percutaneous palliative embolization with enbucrilate is a safe and effective method of treating patients with unresectable renal cell carcinoma. The potential effect of the embolization on cancer progression and improvement of survival in these patients still requires prospective investigation.
Keywords: Aged, 80 and over, Carcinoma, Renal Cell - therapy, Embolization, Therapeutic, Enbucrilate - therapeutic use, Kidney - pathology
Editorial
01 December 2025 : Editorial
Editorial: COVID-19 Six Years on and Endemic Omicron Variants of SARS-CoV-2 Under Monitoring Now Include NB.1.8.1 (Nimbus) and XFG (Stratus)DOI: 10.12659/MSM.952217
Med Sci Monit 2025; 31:e952217
In Press
Clinical Research
A Retrospective Study of the Presentation, Imaging Findings, and Outcomes in 195 Patients with Maxillofacia...Med Sci Monit In Press; DOI: 10.12659/MSM.949933
Clinical Research
Enhanced Eustachian Tube Function and Hearing Recovery with Combined Balloon Dilatation and Tympanic Membra...Med Sci Monit In Press; DOI: 10.12659/MSM.948981
Clinical Research
Virtual Pet–Assisted Therapy to Alleviate Symptoms of Long COVID: A Prospective Pilot Interventional StudyMed Sci Monit In Press; DOI: 10.12659/MSM.950105
Clinical Research
Does Concomitant Biceps Tenotomy Affect Shoulder Proprioception and Strength? A Prospective Intra‑Individua...Med Sci Monit In Press; DOI: 10.12659/MSM.950383
Most Viewed Current Articles
17 Jan 2024 : Review article 10,178,526
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,694,265
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,335,538
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,058
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387






